Skip to Content

Relapse vaccine is a promising treatment for patients with AML

The allogeneic leukemia-derived dendritic cell vaccine – DCP-001 – has shown safety, humoral, and cellular immune responses in the treatment of acute myeloid leukemia. In this MEDtalk Bjorn T. Gjertsen, MD, PhD, Professor of Hematology at the University of Bergen, Norway, presents the effects of the vaccine regarding prognostic factor and relapse of disease. The results are very promising as the vaccine induce deeper responses and support better survival in patients with AML.

Bjørn Tore Gjertsen

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top